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Abstract
Background: Congenital rubella syndrome (CRS) can be prevented with appropriate vaccination
programs. The prevalence rates of rubella and CRS in Iran are unknown; therefore, the risk of
exposure in pregnant women is not clear. The prevalence of CRS in the pre-vaccine period can be
estimated by evaluating the proportion of children in the population with sensorineural hearing loss
attributable to rubella.
Methods: This was a case-control study to estimate prevalence of CRS in Tehran (Iran) by
evaluating the proportion of children with sensorineural hearing loss attributable to rubella. The
study used rubella antibody titer as an indicator, and compared the prevalence of rubella antibody
between children with and without sensorineural hearing loss. Using these findings, the proportion
of cases of sensorineural hearing loss attributable to rubella was estimated.
Results: A total of 225 children aged 1 to 4 years were entered into the study (113 cases and 112
controls). There was a significant difference between cases and controls with regard to rubella
antibody seropositivity (19.5% vs. 8.9%, respectively, odds ratio = 2.47, 95% CI = 1.04–5.97). The
proportion of sensorineural hearing loss cases attributable to rubella was found to be 12%,
corresponding to a CRS prevalence of 0.2/1000.
Conclusion: The prevalence of CRS was approximately 0.2/1000 before rubella vaccination in
Iran, Moreover; the results suggest that implementation of appropriate rubella vaccination
programs could potentially prevent about 12% of cases of sensorineural hearing loss in Iranian
children. This data could potentially be used as baseline data, which in conjunction with an
appropriate method, to establish a surveillance system for rubella vaccination in Iran. An
appropriate surveillance system is needed, because the introduction of a rubella vaccine without
epidemiological data and an adequate monitoring program could result in the shifting of rubella
cases to higher ages, and increasing the incidence of CRS.
Background
Rubella is a common, normally mild disease that mainly
affects children aged 2–12 years. Rubella in pregnancy
may cause abortion, stillbirth and congenital anomalies,
or congenital rubella syndrome (CRS). Prior to the intro-
duction of rubella vaccine in 1969, the disease was distrib-
uted evenly throughout the world. In temperate regions,
the incidence was usually highest in late winter and early
spring. Minor epidemics occurred every 6–9 years, with
major epidemics occurring at intervals ranging from 10 to
30 years [1,2].
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The rubella pandemic in the 1960's clearly demonstrated
the extraordinary teratogenic potential of the rubella
virus. In spite of the fact that 80% of pregnant women
were immune to rubella in the United States, it is esti-
mated that more than 12,500,000 cases of rubella
occurred. Congenital rubella occurred in an estimated
30,000 pregnancies, with 10,000 resulting in fetal death
or therapeutic abortion, and 20,000 resulting in infants
born with CRS [3]. The estimated cost to the US economy
was approximately $2 billion [4].
The incidence of congenital rubella varies in different
populations and depends on the number of susceptible
pregnant women, the circulation of rubella virus, and
rubella vaccination coverage. According to the World
Health Organization (WHO), at least 236,000 CRS cases
occur in every non-epidemic year in developing countries,
and this increase by up to 10 fold during epidemic years
The CRS cases are rarely reported in these countries, and
the extent of the problem remains unknown. However,
the indiscriminate introduction of rubella vaccine with-
out epidemiological data and an adequate monitoring
program should be avoided because the occurrence of
rubella cases can shift to higher ages and increase the inci-
dence of CRS [5].
Rubella is often not notified, as many cases are not seen
by a doctor or even recognized by the patient; conse-
quently, rubella outbreaks can occur without clinical rec-
ognition. Nevertheless, studies in Central and South
America, Africa, India and the Middle and Far East suggest
that rubella is widespread and endemic in most develop-
ing countries [6,7].
The percentage of infection in the fetuses of mothers
infected by rubella during the first trimester of pregnancy
is greater than 80%. As a result, the target group for the
vaccination is all women of childbearing age. Therefore,
the fundamental reason for using the vaccine containing
the rubella antigen is to prevent congenital rubella syn-
drome [8].
In October 2004, CDC convened an independent panel of
internationally recognized authorities on public health,
infectious disease, and immunization to assess progress
toward elimination of rubella and congenital rubella syn-
drome in the United States, a national health objective for
2010. Since rubella vaccine licensure in 1969, substantial
decline in rubella and CRS have occurred, and absence of
endemic transmission in the United States is supported by
recent data: fewer than 25 reported rubella cases each year
since 2001, at least 95% vaccination coverage among
school aged children, estimated 91% population immu-
nity, adequate surveillance to detect rubella outbreaks and
a pattern of virus genotypes consistent with virus originat-
ing in other parts of the world [9].
A rubella vaccination program in the United Kingdom
(UK) was initiated in 1970. Reported cases of CRS
declined from about 50 a year 1971–75 to just over 20 a
year 1986–90, and rubella associated terminations from
an average of 750 to 50 a year [10].
The European Region (EUR) of the World Health Organi-
zation (WHO) comprises 52 member countries, with an
estimated population of 876 million. In 1998, the
Regional Committee for EUR resolved to reduce the inci-
dence of congenital rubella syndrome (CRS) in all coun-
tries to <1 per 100,000 live births by 2010. Large rubella
outbreaks continue to occur in countries that only
recently introduced rubella vaccination (e.g., Russian Fed-
eration and Romania). In many countries, CRS surveil-
lance is not fully implemented, resulting in
underestimates of CRS disease burden, both at country
and regional levels [11]. The introduction of rubella vac-
cine in the infant immunization schedule should only be
considered when coverage>80% can be assured on a long-
term basis [12].
Between December 2003 and January 2004, the Ministry
of Health and Medical Education of the Islamic Republic
of Iran implemented a nationwide campaign to vaccinate
about 32,000,000 people aged 5 to 25 years with a com-
bined measles and rubella (MR) vaccine. Before this cam-
paign, rubella vaccination was not included in the
childhood vaccination schedule. After the campaign, the
Ministry changed the childhood vaccination schedule so
as to include 2 doses of the measles, mump and rubella
(MMR) vaccine, one given at 15 months and the other at
4 to 6 years of age. Before the MR campaign in Iran, the
epidemiology of rubella and congenital rubella was not
clear. There is still no adequate surveillance system in
place for congenital rubella after vaccination. An adequate
surveillance system should monitor the following param-
eters: incidence of CRS, incidence of rubella, rubella
immunity in women of childbearing age, rubella vaccina-
tion coverage and rubella outbreaks.
Retrospective studies on children with abnormalities sim-
ilar to the complications of CRS in developing countries
can estimate the rate of congenital rubella risk in these
children. Cases of rubella-related deafness in children
have been identified by comparing the prevalence of
rubella antibody in children with and without sen-
sorineural deafness. Therefore, a reduction in the number
of deaf children has been used as an indication of reduced
maternal rubella infection after the introduction of
rubella vaccination programs [6]. Sensorineural hearing
loss is one of the most common abnormalities (50%)BMC Infectious Diseases 2005, 5:44 http://www.biomedcentral.com/1471-2334/5/44
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associated with CRS [13]. Hearing loss present at birth is
often not detected until a later age. Hearing loss can also
occur as a delayed manifestation of CRS; and is the most
common complication (80%) with late onset [14]. The
hearing loss is bilateral, sensorineural type in all grades of
severity [12].
Moreover, up to 50% of infections during pregnancy are
sub-clinical, and many go unrecognized. Thus, the esti-
mated incidence of rubella-related deafness (like the other
CRS defects) is likely less than the true incidence [5].
Hearing impairment can result from fetal rubella not only
during the first trimester, but also in the second and third
trimesters of pregnancy [13]. Rubella serology is useful in
epidemiological studies to examine the role of rubella as
a cause of sensorineural hearing loss, because the number
of acquired infections can be estimated from data gath-
ered from controls and cases of rubella-related deafness in
populations of children. The aim of this study was to use
a similar method to estimate the prevalence of CRS by
indicating the proportion of children in the population
with sensorineural hearing loss attributable to rubella.
Methods
A case-control study of 225 children aged 1–4 years was
conducted from November 1995 to May 1996 in Tehran,
Iran. The study compared the prevalence of rubella anti-
body between children with and without sensorineural
hearing loss, and tested the hypothesis that congenital
rubella is associated with an increased risk of sen-
sorineural hearing loss.
The cases were 113 medically confirmed deaf children
admitted to deaf educational centers. The controls were
112 children with normal hearing selected from the sur-
gery ward of Amirkabir hospital in Tehran. One limitation
of this study was the selection of the control group,
because many parents with healthy children were reluc-
tant to allow blood sampling of their children. Therefore,
the control group was taken from among patients at a hos-
pital surgery ward, excluding subjects who may have had
an infectious disease.
It is significant that children under 1 and over 4 years of
age were excluded from the study. In infants (mainly
under 6 months), high levels of rubella antibody passively
transferred from mother to fetus could result in an overes-
timate of seropositivity, while in children over 4 years old,
rubella antibody is usually acquired from a postnatal
infection. Detection of antibody in children 1 to 4 years of
age was used to make a retrospective diagnosis of congen-
ital rubella infection. It is also significant that rubella
infection is most frequent among children 5 to 14 years of
age [15].
During the time period covered by this study, rubella vac-
cination was not included in the national routine child-
hood vaccination; however, some physicians
administered MMR vaccine instead of measles vaccine to
their patients. Therefore, we excluded all children who
had a history of MMR vaccination. History of MMR vacci-
nation was obtained from the vaccination cards of
children.
For all children, data were collected on maternal (prenatal
and delivery) and neonatal histories. In addition, blood
samples were taken from children and the titer of rubella
antibody was determined. The serological technique
employed was the hemagglutination inhibition (HI) test.
Children with rubella HI antibody titers of 1:8 or greater
were regarded as seropositive, and those with titers of less
that 1:8 as seronegative. The Virology Department of the
Public Health School (Tehran University of Medical Sci-
ences) carried out the HI tests. Seropositive children in the
case and control groups were compared using the chi-
squared test and odds ratio (OR). The attributable risk
(AR) was then estimated. The formula for calculating the
AR using the odds ratio for disease in the exposed popula-
tion is:
% Attributable Risk = P (OR-1)/ 1+ P (OR-1)
where P is the exposure prevalence in the controls as long
as the disease is rare and the control group is reasonably
representative of all non-cases in the population (propor-
tion of rubella antibody in the control group), and OR is
the odds ratio for disease in the exposed population.
Finally, we developed the following formula to estimate
the prevalence of CRS:
"Prevalence of CRS = B * C * (1/D) * 1000"
This formula is derived from the following formula:
"Prevalence of CRS = [A * B * C * (1/D) * 1000] / A"
where A is the number of children during the year of
study, B is the prevalence of hearing loss, C is the AR, and
D is the frequency of sensorineural hearing loss following
CRS.
Results
There were 113 children in the case group and 112 chil-
dren in the control group. The case and control groups
consisted of 53% and 47% male subjects, respectively.
This difference was not statistically significant (P = 0.2).
No significant difference was found with regard to age dis-
tribution of cases as compared to controls (P = 0.12). The
mean (SD) age was higher in cases than controls, but thisBMC Infectious Diseases 2005, 5:44 http://www.biomedcentral.com/1471-2334/5/44
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difference was not significant: 2.9 years (SD = 1.1) com-
pared with 2.6 years (SD = 1.3) (P = 0.4).
The percentage of children with rubella antibody in the
case and control groups is shown in Table 1. The percent-
age of children with rubella antibody was significantly
higher in cases than controls: 19.5% compared with 8.9%,
respectively (OR = 2.47, 95% CI 1.04–5.97, P = 0.02).
Therefore, congenital rubella was associated with a signif-
icantly increased (greater than two times) sensorineural
hearing loss in children. The AR was estimated to be about
12%, which indicates that about 12% of the children born
with hearing loss were damaged as a result of congenital
rubella, and thus that it may be possible to reduce the inci-
dence of sensorineural hearing loss by up to 12% by pre-
venting rubella infection in pregnant women.
According to the results of this study, the prevalence of
CRS in Tehran was estimated to be about 0.2/1000 chil-
dren. This prevalence was estimated using the following
data:
A = number of children aged 1 – 4 years in Tehran (1995):
775000 (using national data)
B = prevalence of hearing loss in children: 1/1000 (using
national data)
A*B = children with hearing loss: 775 (expected)
C = attributable risk (derived from the present study):
12%
A*B*C = children with rubella-related deafness: 93 chil-
dren (expected)
D = frequency of sensorineural hearing loss associated
with CRS: 50% (derived from previous studies)
A*B*C*1/D = the number of children with CRS: 186
Therefore:
Prevalence of CRS in Tehran = 186 / 775000 = 0.2/1000
Considering the number of children aged 1 – 4 years in
Iran and the prevalence of CRS estimated here (0.2/1000
children), the present results suggest that tens of CRS cases
could be prevented each year by appropriate vaccination
programs.
Maternal history in sensorineural hearing-impaired chil-
dren (case group) according to rubella antibody status is
shown in Table 2. Nine mothers (41%) of 22 deaf serop-
ositive children reported a history of rubella infection,
rash, or rubella exposure during pregnancy, whereas none
of 91 mothers of seronegative deaf children reported these
events (p = 0.000).
Discussion
The present findings indicate that the prevalence of CRS in
Iran is approximately 0.2/1000 (Before rubella vaccina-
tion in Iran). World Health Organization reported that in
the absence of widespread rubella vaccination, the inci-
dence of CRS varies between 0.1–0.2 per 1,000 live births,
with higher rates (1–4 per 1,000 live births) during epi-
demics [2].
Table 1: Rubella antibody status in hearing impaired (case) and normal control children aged 1–4 years, Tehran, Iran
Rubella antibody status Case n (%) Control n (%) Odds Ratio (95% CI)
Seropositive 22 (19.5) 10 (8.9)
Seronegative 91 (80.5) 102 (91.1) 2.47 (1.04–5.94)
Total 113 (100) 112 (100)
Table 2: Rubella antibody status in sensori-neural hearing-impaired children aged 1–4 years according to maternal history of rubella 
infection, Tehran, Iran
Maternal history of rubella Seropositive n (%) Seronegative n (%) P-value
Positive 9 (41) 0 (0)
Negative 13 (59) 91 (100) 0.000
Total 22 (100) 91 (100)BMC Infectious Diseases 2005, 5:44 http://www.biomedcentral.com/1471-2334/5/44
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During rubella outbreaks, rates of CRS per 1000 live births
were at least 1.7 in Jamaica, 0.7 in Oman, 2.2 in Panama,
1.5 in Singapore, 0.9 in Sri Lanka, and 0.6 in Trinidad and
Tobago. These rates are similar to those reported from
industrialized countries during the pre-vaccine era [16].
The prevalence of bilateral sensorineural hearing loss is
0.5 to 1 newborns per 1000 live births. In addition, the
onset of hearing loss can occur at any time throughout
childhood. Thus, it is estimated that the prevalence of
bilateral hearing loss increases to 1.5–2/1000 children
under the age of 6 years [15]. In Iran, the prevalence of
hearing loss is 1/1000 children [17]. Considering the
prevalence of sensorineural hearing loss, the estimated AR
in this study (12%), it is estimated that congenital rubella
was the cause of deafness in approximately 93 children
aged 1–4 in Tehran in the year considered in the present
study. If we assume that the epidemiology of rubella in
Tehran, the capital city of Iran, is similar to that in other
areas of Iran, we obtain the estimate that in the year of the
present study there were approximately 620 children (1–
4 years) in Iran with deafness that could have been pre-
vented by rubella vaccination.
Some investigations in Iran showed that rubella immu-
nity in women of childbearing age from 1968 through
1995 (the time of this study) fluctuated between 70% and
95% [18-22]. The rate of rubella immunity in this popu-
lation in 1995 was estimated as 80% [23]. Therefore, the
year considered in the present study was a non-epidemic
year, and the number of children born with deafness due
to rubella would be expected to increase in epidemic
years.
Nine mothers (41%) of 22 deaf, seropositive children in
the present study reported a history of rubella, rash, or
rubella exposure during pregnancy. Other studies have
also reported between 40% and 75% of deaf seropositive
children had such a maternal history [24].
In this study, the degree of hearing loss in children who
attended deaf educational centers was often higher than
50 dB (severe to profound hearing loss), and their hearing
loss was bilateral. Thus, children with low severity of deaf-
ness were not included in this study, and the relation
between severity of deafness and congenital rubella could
not be estimated.
About 20% of the children in deaf educational centers
were not included because of a history of MMR (Measles,
Mump and Rubella) vaccination, which may lead to an
underestimation of the OR. Meanwhile, experience in
other countries suggests that if MMR vaccination coverage
is less than 60%–70%, it may actually increase the age of
infection, and therefore the incidence of CRS [1].
After comparing vaccination cards with parents' reports
about vaccination history, it was found that five deaf chil-
dren among the cases actually had a history of MMR vac-
cination, and they were consequently excluded from the
study. Contrary to expectations, rubella antibody titer was
negative in two of these children. Therefore, the efficacy of
MMR vaccine should be investigated in future studies.
According to research done in Iran (during the year of this
study), the rate of rubella immunity has reached about
80% [23]; however, this rate of immunity is similar to that
in other countries during the rubella pandemic of the
1960's, which claimed thousands of victims [3,4]. Epide-
miological evidence has shown that while rubella virus
continues to circulate among children, there is still a risk
of infection in pregnant women, even though only 3% of
them are non-immune, and there is little prospect of elim-
inating CRS [1,25].
The world has now cumulated 35 years of lessons on use
of rubella vaccine, and some striking examples of how
rubella vaccination strategies should and should not be
applied [10,11,26-31]. Most importantly, studies in devel-
oped countries have generated the following recom-
mended vaccination program: routine MMR vaccination
at 12–15 months of age followed by a second dose of
MMR vaccine at 4–6 years (both sexes) [10,32,33]. This
study clearly showed the necessity for suitable rubella vac-
cination program in Iran. However, inadequately imple-
mented childhood vaccination runs the risk of altering
rubella transmission dynamics and can lead to increase
insusceptibility in women of childbearing age with the
potential of increased numbers of cases of CRS. Conse-
quently, it is essential that childhood vaccination pro-
grams achieve and maintain high levels of coverage [12].
Before the MR campaign in Iran, the epidemiology of
rubella and congenital rubella was not clear. In spite of
this unclear epidemiology, rubella vaccination was
launched in Iran (after the time period covered by the
present study). Now, due to limited disease surveillance
and reporting systems, data on the incidence of rubella
and CRS in Iran are scant. This study provides data on the
prevalence of CRS in Iran; this data could potentially be
used as baseline data, which in conjunction with an
appropriate method, to establish a surveillance system for
rubella vaccination in Iran.
Conclusion
Rubella is a common communicable viral disease of
childhood, and rubella in pregnancy may cause CRS.
Sensorineural hearing loss is the most common abnor-
mality associated with CRS, and it is the most common
complication with late onset. The present findings indi-
cate that the prevalence of CRS was approximately 0.2/BMC Infectious Diseases 2005, 5:44 http://www.biomedcentral.com/1471-2334/5/44
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1000 before rubella vaccination in Iran, Moreover; the
results suggest that implementation of appropriate rubella
vaccination programs could potentially prevent about
12% of cases of sensorineural hearing loss in Iranian chil-
dren. This data could potentially be used as baseline data,
which in conjunction with an appropriate method, to
establish a surveillance system for rubella vaccination in
Iran. An appropriate surveillance system is needed
because the introduction of rubella vaccine without epi-
demiological data and an adequate monitoring program
may result in the shifting of rubella cases to higher ages,
and increased incidence of CRS.
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